The initial success of Viagra undeniably reshaped the medication landscape, but placing funds in companies primarily reliant on unbranded versions presents a challenging picture. While early profits were impressive, the cessation of patents and the emergence of cheaper alternatives have diminished market share. Consequently, a thorough analysis of